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Understanding longitudinal changes in %FEV1 variability and its role as an 
indicator of care quality among adults with cystic fibrosis  
 
Background: 
Cystic fibrosis (CF) is a long-term condition whereby regular nebulised medications are needed to 
maintain lung health. %FEV1 decline is traditionally used to indicate lung health, but it is relatively 
insensitive. %FEV1 decline tended to be preceded by %FEV1 variability, suggesting that it is 
potentially a more sensitive outcome measure. Given the consistent improvement in nebuliser 
adherence in Sheffield from 2013-2016, we hypothesised that %FEV1 variability would decrease 
over time. 
 
Aim: 
To determine the year-by-year change in %FEV1 variability in the Sheffield Adult CF Centre from 
2013-2016 
 
Methods:  
FEV1 and other clinical data were retrospectively collected from every adult with CF receiving care 
in Sheffield from 2013-2016, excluding those who had lung transplantation or on ivacaftor. I-neb 
nebuliser data were used to calculate normative adherence.[1] %FEV1 was calculated using the 
GLI-2012 equation. )(9YDULDELOLW\ZDVFDOFXODWHGDVµPHGLDQGHYLDWLRQ¶[2] then categorised into 
µKLJK¶ H[FHHGV WKH(6&)75th centileYV µORZ¶ ZLWKLQ WKH(6&)th centile). Due to non-normal 
distribution and presence of outliers, non-parametric methods were used for the summary measures 
and longitudinal comparisons. 
 
Results: 
208 unique adults with CF provided data for this analysis. Nebuliser adherence increased 
consistently from 2013 (median 32.8%, IQR 14.5 to 58.1%) to 2016 (median 49.6%, IQR 21.9 to 
68.9%), Friedman test p-value 0.004. The rate of %FEV1 decline slowed considerably from 2014-
2015 (median -0.90%, IQR -3.25 to 1.46%) to 2015-2016 (median -0.32%, IQR -2.87 to 1.76%). This 
was preceded by a considerable drop in the proportion of people with high %FEV1 variability from 
2014 (61/162, 37.7%) to 2015 (54/174, 31.0%). Results were summarised in Table 1. 
 
 
Conclusion: 
These results highlight the potential of using %FEV1 variability to detect improvement in care quality 
before changes in %FEV1 decline are detected. Further studies are needed to better understand the 
factors that influence %FEV1 variability and determine the generalisability of these finding. 
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Table1: Summary of 2013-2016 findings  
 2013 
(n = 166) 
2014 
(n = 170) 
2015 
(n = 185) 
2016 
(n = 186) 
 
P-value 
 
People on I-neb, n (%)  
 
 
89 (53.6) 
 
97 (57.1) 
 
104 (56.2) 
 
102 (54.8) 
 
 
% Adherence, median (IQR) 
 
32.8  
(14.5 ± 58.1) 
39.6  
(14.6 ± 65.4) 
42.9  
(18.6 ± 73.8) 
49.6  
(21.9 ± 68.9) 
 
0.004  
 
Annual intravenous antibiotics day, 
median (IQR) 
 
 
14  
(0 ± 35) 
 
14 
 (0 ± 28) 
 
14  
(0 ± 35) 
 
14 
 (0 ± 40) 
 
0.001 
 
BMI in kg/m2, median (IQR) 
 
22.3 
 (19.7 ± 24.6) 
22.7 
 (20.0 ± 25.0) 
23.0  
(20.3 ± 26.0) 
23.2 
 (20.4 ± 26.0) 
 
<0.001 
 
% FEV1, median (IQR) 
 
78.7 
 (54.1 ± 92.5) 
76.6  
(54.4 ± 89.7) 
77.8  
(60.4 ± 89.0) 
78.5  
(58.5 ± 89.6) 
 
<0.001 
 
% FEV1 variability  
 
 
     Median (IQR)        
 
 
     People exceeding 75th centile, (%)        
 
 
(n = 161) 
 
5.0 (2.7 ± 8.5) 
 
61 (37.9) 
 
(n = 162) 
 
4.8 (2.8 ± 7.5) 
 
61 (37.7) 
 
(n = 174) 
 
4.4 (2.6 ± 7.1) 
 
54 (31.0) 
 
(n = 178) 
 
4.2 (2.5 ± 7.0) 
 
53 (29.8) 
 
 
 
0.915 
 
 
0.418Á 
 
Annual %FEV1 change 
 
 
     Median (IQR)        
 
 
     People with decline >2%, (%)        
 
 
 
(n = 158) 
 ±1.09  
(±4.58 to 1.49) 
 
 
69 (43.7) 
 
(n = 162) 
 ±0.90 
(±3.25 to 1.46) 
 
 
63 (38.9) 
 
(n = 176) 
 ±0.32 
(±2.87 to 1.76) 
 
 
56 (31.8) 
 
 
 
0.135 
 
 
0.139Á 
 

 Friedman test      Á&RFKUDQ¶V4WHVW 
 
 
